CPHI India 2025

Visit us to learn how Dr. Reddy’s can be your strategic API partner across markets.

Meet us at Stand RH-E02

25-27 November 2025
India Expo Centre, Greater Noida

Phone

Our Team at CPHI India 2025

Deepak Sapra

CEO, Pharmaceutical Services and Active Ingredients

Dr. A Kalyan Chakravarthy

Executive VP & Head - SEAMEA & B2B Formulations

B Vivek

Executive VP & Global Head - Supply, Demand Planning & Delivery

E Sreedhar

Executive Vice President, Global Regulatory Affairs

Ashwinikumar Kulkarni

Vice President & Global Head - Demand Planning, Customer Support & Program Management

Siddhartha Deshpande

Associate Vice President, API Sales & BD

Netraja J Patil

Associate Director, Turkey, Jordan & Africa

Vishal N Bhojak

Director, Sales & Marketing - India & South Asia

Susmit Dey

Director, Sales & BD – API and B2B Formulations, SSEA

About Dr.Reddy's API Business

We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.

Dr. Reddy’s API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.

150+ APIs
8 Manufacturing sites
More than 1150 drug master files across global markets.
Over 170 ANDAs and 500 DMFs
More than 1000 patents filed, and more than 70 own patents granted
Experience with complex APIs and formulations supporting early market entries
Preferred pharma API supplier for pharma companies in more than 80 countries

Sustainability

Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world.

In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.

What we achieved in the past year:

Our Plants

About CPHI India 2025

CPHI & PMEC India 2025 is the premier gathering for pharmaceutical professionals in the South Asian region, scheduled from November 25–27, 2025 at the India Expo Centre, Greater Noida, Delhi NCR.

This three-day event unites more than 50,000 visitors and hundreds of exhibiting companies from over 120 countries, making it a focal point for innovation, partnerships, and business growth across the pharmaceutical supply chain.

Deep insight into evolving regulatory trends, technology advancements, and market dynamics
A platform to connect with global buyers, suppliers, and decision-makers
Showcases of cutting-edge capabilities across APIs, formulations, machinery, contract services, and more

Visit us to engage in meaningful business conversations on custom projects, scale-ups, and long-term partnerships.

Let’s talk science, scale, and success in Noida.